YOUNG KI KWON
Engineers in Rockville, MD
License number
Virginia 0402051524
Issued Date
Jan 13, 2015
Expiration Date
Jan 31, 2019
Category
Professional Engineer License
Type
Professional Engineer
Address
Address
Rockville, MD
Personal information
See more information about YOUNG KI KWON at radaris.comName
Address
Phone
4923 Webbed Foot Way, Ellicott City, MD 21043
4521 E West Hwy APT 908, Bethesda, MD 20814
3204 Weeping Willow Ct APT 4, Silver Spring, MD 20906
3204 Weeping Willow Ct APT 43, Silver Spring, MD 20906
3203 Wheaton Way APT G, Ellicott City, MD 21043
Professional information
See more information about YOUNG KI KWON at trustoria.com
Antigenic Cloaking And Its Use
Antigenic Cloaking And Its Use
US Patent:
2012003, Feb 9, 2012
Filed:
Feb 6, 2009
Appl. No.:
12/866723
Inventors:
Peter D. Kwong - Washington DC, US
Gary J. Nabel - Washington DC, US
George Shaw - Birmingham AL, US
William Schief - Seattle WA, US
Zhi-yong Yang - Potomac MD, US
Tongqing Zhou - Boyds MD, US
Lei Chen - Rockville MD, US
Young Do Kwon - Rockville MD, US
Gary J. Nabel - Washington DC, US
George Shaw - Birmingham AL, US
William Schief - Seattle WA, US
Zhi-yong Yang - Potomac MD, US
Tongqing Zhou - Boyds MD, US
Lei Chen - Rockville MD, US
Young Do Kwon - Rockville MD, US
International Classification:
A61K 39/21, C07K 14/195, C07K 14/37, C07K 14/005, A61P 31/18, A61K 39/00, C07H 21/00, G01N 33/566, A61P 37/04, C07K 14/16, C07H 21/04
US Classification:
4241881, 530395, 530350, 536 2372, 4241841, 536 231, 4242081, 435 792
Abstract:
Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.